Skip to main content

Table 4 Significant effects of poly-miRTS on chemotherapy response in AML patients by Univariate and Logistic regression analysis

From: Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients

Genotype Total (N) CR, N (%) P OR (95% CI) P a OR (95% CI)a
rs3811810
 GG 167 138 (82.6)   1.00 (reference)   1.00 (reference)
 AA 3 3 (100) 0.999  
 GA 36 35 (97.2) 0.054 7.355 (0.968–55.873) 0.070 6.671 (0.854–52.098)
 AA+GAb 39 38 (97.4) 0.044 7.986 (1.053–60.532) 0.058 7.258 (0.934–56.388)
rs7278
 CC 165 136 (82.4)   1.00 (reference)   1.00 (reference)
 TT 4 4 (100) 0.999  
 TC 37 36 (97.3) 0.049 7.676 (1.011–58.276) 0.053 7.588 (0.971–59.319)
 TT+TCb 41 40 (97.6) 0.038 8.529 (1.127–64.581) 0.040 8.572 (1.106–66.423)
rs1042919
 TT 109 101 (92.7)   1.00 (reference)   1.00 (reference)
 AA 9 7 (77.8) 0.146 0.277 (0.049–1.561) 0.060 0.165 (0.025–1.078)
 AT 88 68 (77.3) 0.003 0.269 (0.112–0.646) 0.003 0.253 (0.102–0.630)
 AA+ATb 97 75 (77.3) 0.003 0.270 (0.114–0.640) 0.002 0.246 (0.100–0.604)
rs3734703
 CC 122 108 (88.5)   1.00 (reference)   1.00 (reference)
 AA 17 16 (94.1) 0.495 2.074 (0.255–16.863) 0.495 2.097 (0.249–17.630)
 CA 67 52 (77.6) 0.050 0.449 (0.202–1.000) 0.066 0.455 (0.197–1.054)
 CC+AA/CAc 139 124 (89.2) 0.030 2.385 (1.087–5.231) 0.023 2.561 (1.136–5.775)
  1. Italic values indicate statistical significance
  2. aAdjusted for age, risk stratifications and platelets
  3. bThe dominant model
  4. cThe overdominance model